Emerging molecular classification in renal cell carcinoma: implications for drug development.
Emerging molecular classification in renal cell carcinoma: implications for drug development.
复制标题
DOI：
10.1007/s11523-010-0144-7
复制
发表时间：
2010-06
影响因子：
5.4
通讯作者：
Rathmell WK
中科院分区：
文献类型：
--
作者：
Hacker KE;Rathmell WK
在过去的十年中，晚期肾细胞癌的靶向治疗取得了进展。然而，随着临床医生可以选择多种治疗方案，我们目前缺乏有效的指标来让医生为特定患者选择最佳治疗方案。对于批准的靶向治疗，可以指示特定肿瘤中药物有效性的潜在分子自然地遵循治疗机制和先前阐明的肿瘤生物学。然而，在晚期肾细胞癌中，使用这些分子作为治疗选择的生物标志物显示出模棱两可的结果，需要进一步研究。除了观察特定的分子靶点外，基于其分子特征的肿瘤亚分类还可以基于治疗益处对患者进行分层，为治疗选择提供信息。此外，这种肿瘤分类方案的持续发展将有望发现其他分子靶点，这些靶点将成为未来RCC疗法的发展保证。使用患者肿瘤的分子分类进行治疗选择将提供机会，以增加目前可用的治疗晚期RCC的有效性，并明智地追求未来RCC治疗的有希望的选择。
In the past decade, progress has been made in the development of targeted therapies for advanced renal cell carcinoma. However, as multiple therapeutic choices become available for clinicians, we currently lack effective indicators to allow physicians to choose the best treatment option for specific patients. For approved targeted therapies, potential molecules that could indicate drug effectiveness in a specific tumor follow naturally from both the therapeutic mechanism and the previously elucidated tumor biology. However, in advanced RCC, the use of these molecules as biomarkers for treatment selection has shown equivocal results and requires further investigation. In addition to looking at specific molecular targets, subclassification of tumors based on their molecular characteristics may also allow stratification of patients based on therapeutic benefits, providing information for treatment selection. Furthermore, the continued development of such tumor classification schemes will hopefully uncover other molecular targets that warrant development as future RCC therapies. The use of molecular classification of patients’ tumors for treatment selection will provide the opportunity to increase the effectiveness of currently available therapies for advanced RCC and to judiciously pursue promising options for future RCC therapies.
登录
查看更多内容
影响因子：
158.5
作者：
Lynch, TJ;Bell, DW;Haber, DA
通讯作者：
Haber, DA
影响因子：
6.6
作者：
Choueiri, Toni K.;Vaziri, Susan A. J.;Ganapathi, Ram
通讯作者：
Ganapathi, Ram
影响因子：
56.9
作者：
Golub, TR;Slonim, DK;Lander, ES
通讯作者：
Lander, ES
影响因子：
45.3
作者：
Cobleigh, MA;Vogel, CL;Slamon, DJ
通讯作者：
Slamon, DJ
影响因子：
45.3
作者：
McDermott, DF;Regan, MM;Atkins, MB
通讯作者：
Atkins, MB